Orthocell LtdASX: OCC

Marine Biomedical Achieves FDA Clearance

· Issued by Orthocell Ltd via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Orthocell Ltd announces that its strategic partner Marine Biomedical has received U.S. FDA clearance for PearlBone, a marine-derived bone graft substitute, marking a significant milestone for the product's commercialization in the U.S. market. This FDA clearance allows PearlBone to be marketed for its approved indications, enhancing Orthocell's biologically driven product portfolio in the bone repair and regeneration sector. The company is optimistic about leveraging its existing U.S. relationships to support PearlBone's market introduction.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/marine-biomedical-achieves-fda-clearance-1

Release

ASX Announcement Orthocell’s Strategic Partner Marine Biomedical Receives U.S. FDA Clearance for PearlBone™ FDA 510(k) clearance unlocks the U.S. market for innovative marine- derived bone regeneration technology, strengthening Orthocell’s biologically driven product portfolio ? Marine...

Orthocell Ltd on 6ix

Story so far

Earlier from Orthocell

All Orthocell news releases